@article {doi:10.1126/science.abl6251,
	title = {Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain},
	journal = {Science},
	year = {2021},
	pages = {eabl6251},
	abstract = {Many studies have examined the impact of SARS-CoV-2 variants on neutralizing antibody activity after they have become dominant strains. Here, we evaluate the consequences of further viral evolution. We demonstrate mechanisms through which the SARS-CoV-2 receptor binding domain (RBD) can tolerate large numbers of simultaneous antibody escape mutations and show that pseudotypes containing up to seven mutations, as opposed to the one to three found in previously studied variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients. We identify an antibody that binds the RBD core to neutralize pseudotypes for all tested variants but show that the RBD can acquire an N-linked glycan to escape neutralization. Our findings portend continued emergence of escape variants as SARS-CoV-2 adapts to humans.},
	doi = {10.1126/science.abl6251} URL = ttps://www.science.org/doi/abs/10.1126/science.abl6251},
	author = {Katherine G. Nabel and Sarah A. Clark and Sundaresh Shankar and Junhua Pan and Lars E. Clark and Pan Yang and Adrian Coscia and McKay, Lindsay G. A. and Haley H. Varnum and Vesna Brusic and Nicole V. Tolan and Guohai Zhou and Micha{\"e}l Desjardins and Sarah E. Turbett and Sanjat Kanjilal and Amy C. Sherman and Anand Dighe and Regina C. LaRocque and Edward T. Ryan and Casey Tylek and Joel F. Cohen-Solal and Anhdao T. Darcy and Davide Tavella and Anca Clabbers and Yao Fan and Griffiths, Anthony and Ivan R. Correia and Jane Seagal and Lindsey R. Baden and Richelle C. Charles and Jonathan Abraham}
}
